Nipocalimab For Myasthenia Gravis and Other Autoantibody Diseases

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=56h8MMzPz0M

Katie Abouzahr, MD, Vice President, Autoantibody Portfolio and Maternal Fetal Disease Area Leader at Johnson Johnson, discusses nipocalimab for the treatment of myasthenia gravis and other autoantibody diseases. • Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. Common symptoms include weakness of the muscles that control: • The eye and eyelid • Facial expressions • Chewing • Talking • Swallowing • Weakness tends to increase during periods of activity and improve after periods of rest. The condition results from a defect in the transmission of nerve impulses to muscles. This is due to the presence of antibodies against the acetylcholine receptor. The exact reason this occurs is not known. • Nipocalimab is a monoclonal antibody that targets FcRn, reducing the levels of circulating immunoglobulin G (IgG) antibody. In addition to myasthenia gravis, the therapy is being developed for other diseases, such as, rheumatoid arthritis, warm autoimmune hemolytic anemia (wAIHA), and maternal fetal diseases, including hemolytic disease of the fetus and newborns. • The phase 3 VIVACITY study is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of nipocalimab in adult patients with generalized myasthenia gravis. As Dr. Abouzahr explains, a statistically significant primary endpoint result of reduction in myasthenia gravis Activities of Daily Living (ADL) score over baseline from weeks 22 to 24 compared to placebo. Also described are the effects of nipocalimab’s rapid onset of action and sustainability. • Dr Abouzahr noted that the next steps for nipocalimab include submission to regulatory bodies to gain approval to treat patients with myasthenia gravis. • To learn more about myasthenia gravis and other rare neurological diseases, visit https://checkrare.com/diseases/neurol... • Chapters: • Intro 00:00 • Myasthenia Gravis Overview 00:50 • Current Management 2:25 • Nipocalimab Overview 4:25 • Clinical Trial Results 7:31 • Next Steps 10:10

#############################

New on site